Chondrocalcinosis, Gout, Osteoarthritis, Rheumatoid Arthritis, Scleroderma, Sjogren's Syndrome, Spinal Disease, Spondylitis, Systemic Lupus Erythematosus
Conditions
Keywords
Regulatory B cells, Rheumatoid arthritis, Biomarker
Brief summary
B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans.
Detailed description
B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans. Main objective: To study Bregs abnormalities in patients with rheumatoid arthritis (RA) at different stages of the disease compared to subjects with mechanical pathologies.Secondary objectives:- To evaluate the specificity of any abnormalities identified in RA by studying Bregs in patients with other autoimmune or other inflammatory joint diseases.- To evaluate the effect of biological and synthetic treatments on Bregs in patients with RA. - To assess whether the rate of Bregs before treatment is predictive of response to biological and synthetic treatments.
Interventions
None listed
Sponsors
University Hospital, Montpellier
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
For RA patients and control patients: * Age over 18 year old * Blood sample taken as part of the usual management * Steroid less than or equal to 15 mg/day and stable for at least a week For RA patients: * Patient with RA meeting the ACR / EULAR 2010 For control patients: * Patients with systemic autoimmune disease (lupus, Sjogren's syndrome, scleroderma) or other inflammatory arthritis (spondylitis, crystals) or a mechanical pathology (limb osteoarthritis or spinal pathology) .
Exclusion criteria
* steroids over 15 mg/day * rituximab infusion in less than 12 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of Bregs levels | 30 months | The levels of Bregs will be assessed in patients with RA and compared to subjects with mechanical pathologies. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of Bregs levels after therapy | 30 months | The levels of Bregs will be assessed in patients who will start a therapy within the framework of their usual follow-up. |
Countries
France
Contacts
Primary ContactJacques Morel, MD, PhD
Backup ContactClaire Daien, MD
Outcome results
None listed